Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NILESH ISHWARLAL LODHIA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1922264654
CMS profile
313976
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$126,524.24

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NILESH ISHWARLAL LODHIA

NPI 1922264654 · CMS profile ID 313976

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922264654?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922264654?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922264654?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NILESH ISHWARLAL LODHIA, NPI 1922264654, CMS profile ID 313976, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1922264654?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $126,524.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $2,367.0009/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535125 CMS
ABBVIE INC. $20.0009/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784513 CMS
ABBVIE INC. $558.6109/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784509 CMS
ABBVIE INC. $98.3909/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784511 CMS
Ferring Pharmaceuticals Inc. $16.7109/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044195269 CMS
ABBVIE INC. $4,025.0009/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784507 CMS
Janssen Biotech, Inc. $14.6109/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436295 CMS
Janssen Biotech, Inc. $35.0209/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436333 CMS
ABBVIE INC. $9.8609/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784503 CMS
ABBVIE INC. $29.6209/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784505 CMS
ABBVIE INC. $558.6109/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784499 CMS
ABBVIE INC. $52.4209/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784501 CMS
Janssen Biotech, Inc. $3,375.0009/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436275 CMS
Janssen Biotech, Inc. $611.5509/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436285 CMS
Janssen Biotech, Inc. $8.8209/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436343 CMS
E.R. Squibb & Sons, L.L.C. $132.8109/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535129 CMS
E.R. Squibb & Sons, L.L.C. $435.0709/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535133 CMS
Celgene Corporation $18.5209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535117 CMS
PFIZER INC. $22.4909/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050429503 CMS
E.R. Squibb & Sons, L.L.C. $2,841.0009/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535105 CMS
Regeneron Healthcare Solutions, Inc. $28.6208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999278037 CMS
Janssen Biotech, Inc. $27.4708/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436363 CMS
Dynavax Technologies Corporation $26.6808/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 985819755 CMS
E.R. Squibb & Sons, L.L.C. $12.9908/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535101 CMS
ABBVIE INC. $14.1608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784497 CMS
E.R. Squibb & Sons, L.L.C. $874.5808/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535097 CMS
E.R. Squibb & Sons, L.L.C. $96.3008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535109 CMS
ABBVIE INC. $20.4608/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784495 CMS
ABBVIE INC. $20.6108/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784493 CMS
Celgene Corporation $38.7508/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535113 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.3408/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055460013 CMS
PFIZER INC. $23.8907/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050522279 CMS
ABBVIE INC. $9.6307/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784491 CMS
Celgene Corporation $12.9307/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535093 CMS
Ferring Pharmaceuticals Inc. $17.0507/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044195259 CMS
Janssen Biotech, Inc. $5,250.0007/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436235 CMS
Janssen Biotech, Inc. $20.7807/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436263 CMS
Janssen Biotech, Inc. $30.3707/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436353 CMS
Janssen Biotech, Inc. $62.4407/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436245 CMS
Janssen Biotech, Inc. $1,065.7507/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436253 CMS
Fresenius Kabi USA, LLC $305.0007/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060078189 CMS
ABBVIE INC. $7.9507/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784489 CMS
Celgene Corporation $20.2807/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015535085 CMS
ABBVIE INC. $25.1906/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784487 CMS
Janssen Biotech, Inc. $99.0406/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436619 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.4106/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055460007 CMS
Janssen Biotech, Inc. $3,375.0006/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436583 CMS
ABBVIE INC. $8.7806/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997784485 CMS
Regeneron Healthcare Solutions, Inc. $33.1806/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999278033 CMS
Janssen Biotech, Inc. $103.9006/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988436591 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,881.22 167
PY2020 $37,758.47 107
PY2021 $90,945.68 165
PY2022 $143,401.47 229
PY2023 $126,524.24 193
PY2024 $105,916.77 160
PY2025 $154,569.61 224

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $153,955.49 119
PY2024 Principal investigator $94,331.65 34
PY2023 Principal investigator $88,969.66 26
PY2022 Principal investigator $129,281.29 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $3,115.52 12/19/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651981
Principal investigator 1 Boehringer Ingelheim International GmbH $2,115.00 12/19/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651983
Principal investigator 1 Boehringer Ingelheim International GmbH $3,916.80 12/19/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651985
Principal investigator 1 F. Hoffmann-La Roche AG $3,500.00 12/04/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211683850
Principal investigator 1 F. Hoffmann-La Roche AG $2,000.00 12/04/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211683852
Principal investigator 1 F. Hoffmann-La Roche AG $9,000.00 12/04/2025 Non-covered Recipient Entity
Wake Forest University Health Sciences
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211683854
Principal investigator 1 Boehringer Ingelheim International GmbH $3,192.32 11/13/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651979
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651987
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651989
Principal investigator 1 Boehringer Ingelheim International GmbH $5.60 10/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651991
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 10/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651993
Principal investigator 1 Boehringer Ingelheim International GmbH $3,660.80 10/22/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651975
Principal investigator 1 Boehringer Ingelheim International GmbH $210.34 10/14/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651973
Principal investigator 1 Boehringer Ingelheim International GmbH $24.14 10/10/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651971
Principal investigator 1 ABBVIE INC. $1,304.39 10/09/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404330
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651955
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651957
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651959
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651961
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651963
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651965
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651967
Principal investigator 1 Boehringer Ingelheim International GmbH $18.58 09/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651969
Principal investigator 1 ABBVIE INC. $2,500.00 09/05/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202510166
Principal investigator 1 ABBVIE INC. $1,500.00 09/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202509148
Principal investigator 1 ABBVIE INC. $3,865.00 09/04/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202509224
Principal investigator 1 ABBVIE INC. $12,500.00 09/04/2025 Non-covered Recipient Entity
ATRIUM HEALTH FOUNDATION
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202509226
Principal investigator 1 ABBVIE INC. $556.37 08/26/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404308
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 08/26/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651945
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 08/26/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651947
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 08/26/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651949
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 08/26/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651951
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 08/26/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651953
Principal investigator 1 ABBVIE INC. $191.02 08/20/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202505213
Principal investigator 1 ABBVIE INC. $50.00 08/19/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404304
Principal investigator 1 ABBVIE INC. $4,605.87 08/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202502258
Principal investigator 1 ABBVIE INC. $13,000.00 08/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202502779
Principal investigator 1 ABBVIE INC. $1,623.68 08/05/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404288
Principal investigator 1 ABBVIE INC. $1,953.67 08/05/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202404297
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/30/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651929
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 07/30/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651933
Principal investigator 1 Boehringer Ingelheim International GmbH $9,000.00 07/30/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651935
Principal investigator 1 ABBVIE INC. $5,000.00 07/22/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202404281
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/14/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651927
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/14/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651931
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/14/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651937
Principal investigator 1 ABBVIE INC. $126.50 07/02/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202404269
Principal investigator 1 ABBVIE INC. $52.00 07/02/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202496375
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651939
Principal investigator 1 Celgene Corporation $4,700.00 06/12/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306349
Principal investigator 1 ABBVIE INC. $146.74 06/03/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202404253
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651943
Principal investigator 1 ABBVIE INC. $3,465.00 05/20/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202485515
Principal investigator 1 Boehringer Ingelheim International GmbH $1.89 05/07/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651917
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 05/07/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651919
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/07/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651921
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/07/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651923
Principal investigator 1 ABBVIE INC. $1,304.39 05/06/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404241
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651925
Principal investigator 1 Boehringer Ingelheim International GmbH $225.00 04/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651903
Principal investigator 1 Boehringer Ingelheim International GmbH $3,600.00 04/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651905
Principal investigator 1 Boehringer Ingelheim International GmbH $210.34 04/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651907
Principal investigator 1 Boehringer Ingelheim International GmbH $36.21 04/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651909
Principal investigator 1 Boehringer Ingelheim International GmbH $161.00 04/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651911
Principal investigator 1 Celgene Corporation $8,165.00 04/10/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306275
Principal investigator 1 Celgene Corporation $500.00 04/10/2025 Covered Recipient Teaching Hospital
Atrium Health Cabarrus
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 1222306325
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651913
Principal investigator 1 ABBVIE INC. $1,500.00 03/25/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202465844
Principal investigator 1 ABBVIE INC. $6,202.00 03/20/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404214
Principal investigator 1 ABBVIE INC. $500.00 03/20/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202465323
Principal investigator 1 ABBVIE INC. $95.00 03/13/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202463711
Principal investigator 1 ABBVIE INC. $50.00 03/11/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404207
Principal investigator 1 ABBVIE INC. $1,257.82 03/06/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202404196
Principal investigator 1 ABBVIE INC. $59.46 03/06/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202404203
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651915
Principal investigator 1 ABBVIE INC. $2,526.00 02/06/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202449435
Principal investigator 1 ABBVIE INC. $5,130.56 02/05/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404176
Principal investigator 1 ABBVIE INC. $6,207.24 02/05/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202404181
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651941
Principal investigator 1 ABBVIE INC. $3,253.00 01/29/2025 Non-covered Recipient Entity
WAKE FOREST UNIVERSITY
M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202441877
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651887
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651889
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651891
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651893
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651895
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651897
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651899
Principal investigator 1 Boehringer Ingelheim International GmbH $146.55 01/27/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651901
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 01/24/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651977
Principal investigator 1 Boehringer Ingelheim International GmbH $49.01 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651839
Principal investigator 1 Boehringer Ingelheim International GmbH $143.55 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651841
Principal investigator 1 Boehringer Ingelheim International GmbH $10.98 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651843
Principal investigator 1 Boehringer Ingelheim International GmbH $244.84 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651845
Principal investigator 1 Boehringer Ingelheim International GmbH $27.14 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651847
Principal investigator 1 Boehringer Ingelheim International GmbH $20.65 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651849
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651851
Principal investigator 1 Boehringer Ingelheim International GmbH $14.51 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651853
Principal investigator 1 Boehringer Ingelheim International GmbH $33.12 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651855
Principal investigator 1 Boehringer Ingelheim International GmbH $133.57 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651857
Principal investigator 1 Boehringer Ingelheim International GmbH $39.24 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651859
Principal investigator 1 Boehringer Ingelheim International GmbH $37.57 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651861
Principal investigator 1 Boehringer Ingelheim International GmbH $71.76 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651863
Principal investigator 1 Boehringer Ingelheim International GmbH $341.63 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651865
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651869
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651871
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651873
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651875
Principal investigator 1 Boehringer Ingelheim International GmbH $7.33 01/23/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651877
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 01/22/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651867
Principal investigator 1 Boehringer Ingelheim International GmbH $398.00 01/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651995
Principal investigator 1 Boehringer Ingelheim International GmbH $1,040.00 01/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651997
Principal investigator 1 Boehringer Ingelheim International GmbH $13.00 01/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651999
Principal investigator 1 Boehringer Ingelheim International GmbH $23.00 01/21/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220652001
Principal investigator 1 ABBVIE INC. $717.88 01/07/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD) No dispute reported 06/30/2026 1202404156
Principal investigator 1 ABBVIE INC. $170.37 01/02/2025 Covered Recipient Teaching Hospital
ATRIUM HEALTH CABARRUS
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202404152
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651879
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 01/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651881
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651883
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 01/01/2025 Non-covered Recipient Entity
Atrium Health Gastroenterology And Hepatology Morehead Medical Plaza
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220651885